Vietnamese Investors Back Novel Point-of-Care Technology for Rapid Detection of Pathogens
Wednesday, December 11, 2019 - 12:50
in Mathematics & Economics
Hememics Biotechnologies Inc., ("Hememics" or the "Company") announced that AMVI Partners, a consortium of high net worth Vietnamese investors, has invested $2.5 million into Hememics. The company will use the funds to initiate clinical research for supporting a U.S. Food and Drug Administration (FDA) submission of a novel point-of-care technology for detection of pathogens in under a minute.